Title : Towards integrated biodesign-inspired translational platforms to co-develop innovative biotechnologies, biomanufacturing and biomarket-ing to revolutionize the future of the personalized & precision healthcare and life science bioindustry
Abstract:
As the worldwide experience and practice say, the efficiency and efficacy of the National Economy are determined by the innovative trends, generated by fresh knowledge and their transfer into the advanced scientific & industrial, social and upgraded healthcare areas, to maintain the development of the coun-try. In this context, Personalized & Precision Medicine (PPM) as a new model of Healthcare Services, is the unique entity demonstrating an Integration of Systems Biology & Trans-Disciplinary Life Scienc-es, Synthetic Biology & Biodesign, and Biodesign-driven translational applications, supported by Healthcare bioinformatics & Big Data Analytics, whilst integrating platforms of Fundamental Sciences and Clinical Applications through the multi-OMICS resources & technologies.
To get PPM model armed in accordance with the latest design-inspired innovations, and achieve the implementation of the upgraded PPM-related unique armamentarium into clinical practice, it is neces-sary to create a new biomarker-driven targeted and Hi-Tech controlled strategy based upon: (i) design-driven biotechnologies; (ii) biomaterials; (iii) developmental engineering paradigm; (iv) translational applications and (v) biomanufacturing & biomarketing. Translational researchers, biodesigners and manufacturers are beginning to realize the promise of PPM, translating to direct benefit to patients or persons-at-risk.
The accent of PPM-driven multi-OMICS portfolio focuses on multi-OMICS technologies, including companion diagnostics & nanotheranostics, molecular imaging, biochemical engineering and biocataly-sis, stem cell, gene and targeted therapies, personalized vaccinomics and related subareas.
One of the latest innovations is becoming design-driven biochemical engineering and biocatalysis, aim-ing at creating a new generation of supramolecular materials in order to develop personalized treatment and vaccines. The latest and future trends point toward the development of special catalytic platforms based on enzymes, ribozymes and abzymes that combine biological precision with enhanced and unique functionality. Biocatalysis and its final products being at the crossroads of systems biology, immuno-chemistry and biochemical engineering, represent a cutting-edge discipline with the power to reshape how we approach chemical reactions and synthesis processes. Among the latest priorities to be pre-selected to act the dominant role in design-driven bioengineering and biotech are biocatalyst-driven drug discovery & development integrated with drug nanodelivery.
Globally, nanobiotechnologies demonstrate a broad spectrum of nanodiagnostic and nanotherapeutic modalities as promising strategies in targeted and smart therapies, and promote a special field of bioin-terface engineering to guide the interactions of surfaces and environmental factors with biocatalysts, biomolecules and cells for optimizing diagnostic manipulations and targeted drug delivery procedures.
So, partnering and forming strategic alliances between researchers, biodesigners, clinicians, business, regulatory bodies and government can help ensure an optimal development program that leverages the Academia and industry experience and FDA’s new and evolving toolkit to speed our way to getting new tools into the innovative markets.
The global PPM-driven and Biodesign-inspired market size was worth at USD 654.46 billion in 2025 and is predicted to reach over USD 1,397.63 billion by 2035. The factors driving the global PPM market include an increase in the prevalence of various types of cancer and hereditary disorders, the affordabil-ity of PPM-guided therapy in cancer drugs and other disease indications.
Healthcare is undergoing a transformation, and it is imperative to leverage new technologies to support the advent of PPM. Therefore, it is urgently needed to discover, to develop and to create new (targeted and/or smart/intelligent) drugs and precision diagnostic tools. This is the reason for developing global scientific, clinical, social, and educational projects in the area of PPM and design-driven translational medicine to elicit the content of the new trend.
The increasing investments in PPM-driven research are generating a significant market opportunity as they broaden the pipeline of novel biomarkers, targeted treatments, genomic assessments, and AI-driven analysis tools. In general, increasing research funding is creating new sources of revenue by en-hancing the scalability, clinical validation, and accessibility of PPM within healthcare systems. All these factors would drive the market growth in the coming years.
The latter would provide a unique platform for collaboration among thought leaders and stakeholders in government, academia, industry, foundations, and disease and patient advocacy with an interest in im-proving the system of healthcare delivery on one hand and drug discovery, development, and transla-tion, on the other one, whilst educating the policy community about issues where biomedical science and policy intersect
